Cell coding company bit.bio has launched a new disease model cell offering enabling scientists to commission disease-relevant mutation of interest. The company’s new Custom ioDisease Model Cells offering lets scientists choose the disease-relevant mutation they’re interested in. The disease-relevant mutation is engineered into bit.bio’s human ioWild Type … Read More
Steve Wowk, VP, Business Unit and General Management of Integrated DNA Technologies, shared with DDW the value of CRISPR-Cas9 in drug discovery. Some of the most important breakthroughs in pharmaceutical research were adapted from naturally occurring phenomena. The CRISPR-Cas9 system, awarded the Nobel Prize in Chemistry in 2020 for its… Read More
A new approach that delivers a ‘one-two punch’ to help T cells attack solid tumours is the focus of a preclinical study by researchers from the Perelman School of Medicine at the University of Pennsylvania. The findings showed that targeting two regulators that control gene functions… Read More
Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity. In this early research, Khalid Shah, Professor of Neurosurgery at Harvard Medical School and Brigham and Women’s Hospital, and colleagues tested the vaccine in an advanced mouse model of brain… Read More
News round-up for 10-14 October by DDW Digital Content Editor Diana Spencer The top news in the world of drug discovery this week reflects the vital importance of collaboration, partnership and support within this industry. Partnerships… Read More
A team of researchers at Northwestern University in the US has devised a new platform for gene editing that could inform the future application of CRISPR-based therapeutics. Using chemical design and synthesis, the team brought together the Nobel-prize winning technology with therapeutic technology born in their own lab to overcome… Read More
Join DDW, supported by Horizon Discovery for this exclusive free event which will examine CRISPR-Cas9 screening and how it offers a powerful approach to advancing drug discovery and the understanding of genetic disease. The event will take place on 9 June 2022, 3PM BST. Register for free here. Joanna… Read More
Join DDW, supported by Horizon Discovery for this exclusive free event which will examine CRISPR-Cas9 screening and how it offers a powerful approach to advancing drug discovery and the understanding of genetic disease. The event will take place on 9 June 2022, 3PM BST. Register for free here. Joanna… Read More
Join DDW, supported by Horizon Discovery for this exclusive free event which will examine CRISPR-Cas9 screening and how it offers a powerful approach to advancing drug discovery and the understanding of genetic disease. The event will take place on 9 June 2022, 3PM BST. Register for free here. Joanna… Read More
